Immune Response and Disease Flares Low in SLE Patients Following COVID Vaccination

August 17, 2021

Recently, the results of a study focusing on patients with systemic lupus erythematosus (SLE) who were fully vaccinated against COVID-19 was published, making it the first study of its kind. The 90 SLE patients participating in the study were recruited from the NYU Lupus Cohort and were compared against a group of 20 healthy controls with no known rheumatological diseases. Controls had only received the Pfizer-BioNTech and Moderna vaccines, whereas SLE patients received all three vaccines in the U.S., which includes the Johnson and Johnson vaccine. Overall, nearly 30% of SLE patients had a lower immune response to the COVID-19 vaccine than the control group. The low levels of response to the vaccine were likely associated with taking non-antimalarial immunosuppressant medications.

In addition to immune response following vaccination, disease flares were also assessed in the study. Flares were low post-vaccination, with 11.4% of patients reporting a mild to moderate flare, and 1.3% having a severe flare. 





Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.